Replies to post #508515 on Anavex Life Sciences Corp (AVXL)

[Hosai]

Technically doing a head to head on these endpoints with Lecanumab:

Plasma Aß42/40

Blarcamesine (48w):
Delta vs placebo: +0.013 (p = 0.048)

Lecanemab (18m):
12 m: change 0.008 vs 0.001 placebo (delta 0.007), p < 0.01
18 m: change 0.008 vs 0.002 placebo (delta 0.006), p < 0.01

= Blarcamesine very mildly higher effect size difference.

Plasma NfL

Blarcamesine (approx, 48 w):
Placebo change ˜ +5 pg/mL
Drug change ˜ +1.5 pg/mL

Approx delta -3.5 pg/mL, so ~70% smaller rise (p = 0.28)

Lecanemab (18 m):

Placebo change +2.9 pg/mL
Drug change +1.8 pg/mL

Delta -1.1 pg/mL, p = 0.06.

= Blarcamesine notably higher effect size but further away from stat sig (technically neither drug was stat sig for NF-l).

PTAU 181

Placebo change = +10 pg/mL
Drug change = about +4 pg/mL

Delta ˜ -6 pg/mL (drug is 6 pg/mL lower than placebo at 48 weeks) (p=0.39). That’s roughly a 60% smaller rise than placebo.

Lecanumab

Placebo change from baseline: about +0.201 pg/mL
Drug change from baseline: about -0.575 pg/mL

Delta ˜ -0.776 pg/mL (drug is 0.776 pg/mL lower than placebo) (p= less than 0.001).

With this one I'm not sure the comparison is relevant as there appears to be completely different scales.

All in all, considering this is clearly a weaker point for Blarcamesine, it does seem interesting to note on pure effecy difference vs placebo delta it's actually better than Lecanumab for nf-L and Plasma 42/40. Also Nf-L not stat sig for Lecanameb despite a much larger 'n' which some may not have realized.